Skip to main content
OpenTrials
Completed

NCT Number: NCT02994277

Artificial Pancreas in Latin America

The purpose of this study is to use closed-loop systems with the algorithms designed by the University of Virginia and by the Instituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) to determine the infusion of insulin in a prolonged period of time in patients with type 1 diabetes mellitus (T1DM).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Aims:

  • To test University of Virginia closed-loop algorithm with meal announcement for 36 hours at our facilities.
  • To test the ability of the closed-loopInstituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) algorithm without meal announcement to maintain glucose control for 2 periods of 12 hours

In both cases, the adequate operation of the system will be considered verified if the system works properly at least 80% of the total connection time .

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient have been diagnosed with T1DM at least two years ago and have been using an insulin pump and a CGM for at least 6 months prior to the trial first visit.
  • Patient is >18 and <65 years.
  • Patient has HbA1c > 6.5 % and < 10%.
  • Woman in premenopausal age agrees to use contraceptive methods.
  • Woman in premenopausal age has negative B-HCG in the tests performed in the trial.
  • Patient is trained in carbohydrates counting.
  • Patient has signed informed consent and has the ability to understand the nature and intent of the study including the ability to comply with study procedures and is willing to keep scheduled visits.

Exclusion criteria

  • Patient has been hospitalized for diabetic ketoacidosis in the last 12 months.
  • Patient has experienced severe hypoglycemia with loss of consciousness in the last 12 months.
  • Patient has a history of coronary disease or cardiac failure.
  • Patient with uncontrolled arterial hypertension.
  • Patient with a condition that makes the researcher believe that it might increase the chance of hypoglycemia.
  • Patient has symptoms compatible with an active infectious disease.
  • Patient has Cystic Fibrosis.
  • Pregnant women, or women with the intention of getting pregnant; women breastfeeding.
  • Patient has been hospitalized for psychiatric treatment in the last 6 months.
  • Patient with a diagnosis of an adrenal disease.
  • Patient has abnormal laboratory values for liver function: transaminase > 2x upper limit of normal.
  • Patient has abnormal laboratory values for renal function: GFR < 60 ml/min/1.73m2
  • Patient has active gastroparesis.
  • Patient is under oncological treatment.
  • Patient has taken acetaminophen 72 hours previous to the study.

Treatment and study plan

1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm

Device

The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.

Primary outcomes

  1. System connectivity

    Time frame: 36 hours

    Adequate operation of the system will be considered verified if the system works properly at least 80% of the total connection time.

Secondary outcomes

  1. Technical fail rate

    Time frame: 36 hours

  2. Percentage of time in glycaemia between 70-180 mg/dl

    Time frame: 36 hours

  3. Percentage of time in glycaemia between 181-250 mg/dl

    Time frame: 36 hours

  4. Percentage of time in hypoglycaemia defined as <70 mg/dl

    Time frame: 36 hours

  5. Percentage of time in hyperglycaemia defined as >180 mg/dl

    Time frame: 36 hours

  6. Number of all hypoglycaemic events (syntomatic and non syntomatic)

    Time frame: 36 hours

  7. Comparison of glycaemic profiles during the trial with glycaemic profiles in the days before the trial

    Time frame: 36 hours

  8. Meal composition's effect in the efficacy of the system to control glycaemia

    Time frame: 36 hours

Sponsors and collaborators

Lead sponsor

Hospital Italiano de Buenos Aires

Other

Collaborators

  • Fundación Nuria/Cellex
  • Instituto Tecnológico de Buenos Aires
  • Universidad Nacional de La Plata
  • Universidad Nacional de Quilmes
  • University of Virginia

Registry information

Official study title

Pilot Study of Automatic Glycaemic Correction Systems (Closed-loop) in Patients With Type 1 Diabetes Mellitus With Continuous Subcutaneous Insulin Infusion

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Dec 15, 2016
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.